Application of manidipine combined temozolomide and pharmaceutical composition thereof in preparation of drug for treating brain glioma

Abstract

The invention discloses application of manidipine combined temozolomide and a pharmaceutical composition thereof in preparation of a drug for treating brain glioma. The manidipine combined temozolomide can obviously enhance the treatment effect of temozolomide on brain glioma and helps reduce the dosage of temozolomide, thus providing a new treatment scheme for treatment of brain glioma.

Description

technical field [0001] The invention relates to the field of drug therapeutics, in particular to the application of manidipine in combination with temozolomide and its drug combination in the preparation of drugs for treating brain glioma. Background technique [0002] Malignant glioma is currently the most common brain tumor. It not only has a high incidence rate, but also has a low cure rate. It has the characteristics of high mortality and high infiltration, and poses a great threat to human health. Because it is often interlaced with normal brain tissue, surgical resection often cannot completely eradicate it, which brings great resistance to the clinical treatment of patients. Studies have shown that even after surgery, radiotherapy and chemotherapy, the survival period of patients with malignant glioma is only 12-15 months, and the five-year survival rate is only about 2%; Relapse, the survival time from the first relapse to the patient's death is about 7 months. At ...

AI Technical Summary

Problems solved by technology

[0006] So far, manidipine has not been reported to enhan

Images